Replies to post #255229 on Biotech Values

[xavierprivas]

Change in trial protocol allowing continuing therapy with Criz and Endari for patients while previously it was excluded. Don't know if this explained the stock price. Only thing of note I could find.

https://clinicaltrials.gov/study/NCT05169580?spons=Fulcrum%20Therapeutics&tab=history&a=22&b=23&compareMode=sideBySide#version-content-panel